Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia
- Autori: Schimmenti C.; Sucato V.; Manzone E.; Cancellieri G.; Mortillaro F.; Novo G.; Galassi A.R.; Venturella F.
- Anno di pubblicazione: 2021
- Tipologia: Articolo in rivista
- Parole Chiave: atherosclerosis; bempedoic acid; lipid-lowering therapy; low-density lipoprotein; statins
- OA Link: http://hdl.handle.net/10447/513660
Abstract
Statin therapy has been the cornerstone for the reduction of cholesterol and circulating low-density lipoprotein (LDL) in patients with cardiovascular diseases. However, statin monotherapy has disadvantages attributable to myopathies and to the insufficient cholesterol reduction observed in some patients. There is a need for new well-tolerated therapies for lowering LDL. This review will focus on bempedoic acid in combination with traditional statin therapy or other lipid-lowering agents and its emerging role in LDL-C lowering. Bempedoic acid is also a viable alternative for reducing LDL cholesterol in the treatment of some patients suffering from heterozygous familial hypercholesterolemia.